ClinicalTrials.gg
RecruitingNCT07740551Updated Nov 4, 2026

Comparison of Individuals With Primary Ciliary Dyskinesia and Healthy Controls

An observational study in Primary Ciliary Dyskinesia (PCD), sponsored by Izmir Democracy University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 6 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Izmir Democracy University · Observational

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Nov 4, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓
Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
30
Ages
6 Years to 18 Years
Sex
All
01

Study summary

To date, the literature has not yet elucidated the status of malnutrition and sarcopenia in children and adolescents with PCD compared to healthy controls. Therefore, the aim of this study is to compare the nutritional and sarcopenia status of children and adolescents with primary ciliary dyskinesia to that of healthy controls.

Read the detailed description

Primary ciliary dyskinesia (PCD) is an autosomal recessive disorder characterized by abnormal ciliary motility and impaired mucociliary clearance, caused by mutations in the genes responsible for ciliary movement. Structural or functional defects of the cilia lead to chronic upper and lower respiratory tract infections, fertility issues, and organ asymmetry. Activities of daily living predominantly consist of movements requiring short-term and repetitive anaerobic performance, and in children particularly, physical activities generally involve brief, low-to-moderate intensity exertion. However, in children with PCD, factors such as pulmonary dysfunction, malnutrition, and decreased physical activity levels can adversely affect anaerobic exercise capacity.

02

Conditions studied

  • Primary Ciliary Dyskinesia (PCD)

Keywords

  • primary ciliary dyskinesia (PCD)
  • sarcopenia
  • respiratory function test
  • malnutrion
03

In context

Ciliary Motility Disorders

79 studies on the registry are indexed under Ciliary Motility Disorders; 26 are open to participants now.

This study's planned enrollment of 30 is below the median of 130 across 55 observational studies indexed under Ciliary Motility Disorders.

Browse Ciliary Motility Disorders studies →

Lead sponsor

Izmir Democracy University is the lead sponsor of 78 studies on the registry; 32 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

At least 15 patients with primary ciliary dyskinesia will be included in the main group and at least 15 healthy individuals will be included in the control group.

Eligibility criteria

Inclusion Criteria for Children and Adolescents with Primary Ciliary Dyskinesia:

  • To be between the ages of 6-18
  • To have been diagnosed with primary ciliary dyskinesia
  • To be clinically stable for at least 3 weeks
  • To have the necessary cooperation for the measurements
  • To volunteer to participate in the study

Inclusion Criteria for Healthy Children and Adolescents:

  • To be between the ages of 6-18
  • To be in a similar average and ratio with the group of children and adolescents with primary ciliary dyskinesia in terms of age and gender
  • To have the necessary cooperation for the measurements
  • To volunteer to participate in the study

Exclusion Criteria for Children and Adolescents with Primary Ciliary Dyskinesia:

  • Having any orthopedic, neurological, psychological or cardiovascular problem that may prevent the measurements from being performed in the last 6 months
  • Smoking or quitting smoking

Exclusion Criteria for Healthy Children and Adolescents:

  • Having any orthopedic, neurological, psychological or cardiovascular problem that may prevent the measurements from being performed in the last 6 months
  • Having any chronic disease
  • Smoking or quitting smoking
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
30 participants (estimated)
Patient registry
No

Groups and cohorts

  • Primary Ciliary Dyskinesia Group

    This group will consist of children and adolescents with primary ciliary dyskinesia group.

    Other: Physical Evaluations in Children with Primary Ciliary Dyskinesia

  • Control Group

    This group will consist of healthy children and adolescents.

    Other: Physical Evaluations in Healthy Children

Interventions

  • OtherPhysical Evaluations in Children with Primary Ciliary Dyskinesia

    In this study, malnutrition and sarcopenia status in children and adolescents diagnosed with primary ciliary dyskinesia will be evaluated. All data pertaining to these assessments will be acquired via face-to-face interviews with a duration of 45 to 60 minutes.

  • OtherPhysical Evaluations in Healthy Children

    In this study, malnutrition and sarcopenia status in children and adolescents diagnosed with primary ciliary dyskinesia will be evaluated. All data pertaining to these assessments will be acquired via face-to-face interviews with a duration of 45 to 60 minutes.

06

What researchers measure

Primary outcomes

  1. Hand Grip Strength

    Handgrip strength (kg) will be assessed twice in each hand using a dynamometer (Jamar) with a maximal isometric contraction lasting approximately 2 seconds. The best result (kg) will be used for data analysis.

    Time frame: through study completion, an average of 1 year

Secondary outcomes

  1. Vertical Jump Power

    Vertical jump test, participants will assume a jumping position with their hands resting at the waist and their feet spaced pelvis-width apart. Participants will perform one practice jump and three test jumps. The highest of the three test jumps will be used for data analysis.

    Time frame: through study completion, an average of 1 year

  2. Core muscle strength

    Core muscle strength was assessed using the plank test (Plank, s) in which the body weight was supported by the toes and forearms. The test was terminated when participants were unable to maintain posture or their pelvis moved up or down five or more cm, measured using a ruler. The test was also ended if participants remained in the plank position for 3 minutes (highest score).

    Time frame: through study completion, an average of 1 year

  3. Waist circumference measurement

    Waist circumference measurement is the assessment of abdominal fat by measuring the distance around the narrowest part of the torso, usually just above the hip bones. It is a simple indicator used to evaluate central obesity and the risk of metabolic and cardiovascular diseases.

    Time frame: through study completion, an average of 1 year

  4. Malnutrition Risk Score of participants

    Screening Tool for Risk on Nutritional Status and Growth will used to evaluate malnutrition risk score. Total score of this tool ranges from 0 to 5; 0 shows low risk score while 5 shows high risk score.

    Time frame: through study completion, an average of 1 year

  5. Body Fat Percentage

    Body fat percentage is the proportion of fat mass compared to total body weight. It is an important indicator of overall health and fitness, reflecting the balance between fat and lean body tissues.

    Time frame: through study completion, an average of 1 year

  6. Forced Vital Capacity

    Forced Vital Capacity will be measured via spirometry.

    Time frame: through study completion, an average of 1 year

  7. Forced Expiratory Volume in 1 second

    Forced Expiratory Volume in 1 second will be measured using spirometry.

    Time frame: through study completion, an average of 1 year

  8. Forced Expiratory Volume in 1 second Forced Vital Capacity Ratio

    This value will be measured using spirometry. This ratio compares the amount of air exhaled in the first second to the total exhaled air. It is used to differentiate between obstructive and restrictive lung disorders.

    Time frame: through study completion, an average of 1 year

  9. Peak Expiratory Flow

    This value will be measured using spirometry.

    Time frame: through study completion, an average of 1 year

  10. Forced Expiratory Flow at 25-75%

    This value will be measured using spirometry.

    Time frame: through study completion, an average of 1 year

  11. Hip circumference measurement

    Hip circumference measurement is the process of measuring the distance around the widest part of the hips and buttocks using a measuring tape. It is commonly used to assess body fat distribution and calculate ratios like the waist-to-hip ratio.

    Time frame: through study completion, an average of 1 year

  12. upper middle arm circumference measurement

    Upper middle arm circumference (MUAC) measurement is the process of measuring the circumference of the upper arm at the midpoint between the shoulder and the elbow using a measuring tape. It is commonly used to assess nutritional status, especially in children and adults in clinical or field settings.

    Time frame: through study completion, an average of 1 year

  13. Triceps skinfold thickness

    Triceps skinfold thickness is the measurement of the thickness of a fold of skin and subcutaneous fat at the back of the upper arm using calipers. It is used to estimate body fat percentage and assess nutritional status.

    Time frame: through study completion, an average of 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Baptista, F., Zymbal, V., & Janz, K. F. (2022). Predictive validity of handgrip strength, vertical jump power, and plank time in the identification of pediatric sarcopenia. Measurement in Physical Education and Exercise Science, 26(4), 361-370. https://doi.org/10.1080/1091367X.2021.1987242
  • Goutaki M, Halbeisen FS, Spycher BD, Maurer E, Belle F, Amirav I, Behan L, Boon M, Carr S, Casaulta C, Clement A, Crowley S, Dell S, Ferkol T, Haarman EG, Karadag B, Knowles M, Koerner-Rettberg C, Leigh MW, Loebinger MR, Mazurek H, Morgan L, Nielsen KG, Phillipsen M, Sagel SD, Santamaria F, Schwerk N, Yiallouros P, Lucas JS, Kuehni CE; PCD Israeli Consortium; Swiss PCD Group; French Reference Centre for Rare Lung Diseases. Growth and nutritional status, and their association with lung function: a study from the international Primary Ciliary Dyskinesia Cohort. Eur Respir J. 2017 Dec 21;50(6):1701659. doi: 10.1183/13993003.01659-2017. Print 2017 Dec. PubMed 29269581 ↗
  • Denizoglu Kulli H, Gurses HN, Zeren M, Ucgun H, Cakir E. Do pulmonary and extrapulmonary features differ among cystic fibrosis, primary ciliary dyskinesia, and healthy children? Pediatr Pulmonol. 2020 Nov;55(11):3067-3073. doi: 10.1002/ppul.25052. Epub 2020 Sep 11. PubMed 32877003 ↗
  • Firat M, Bosnak-Guclu M, Sismanlar-Eyuboglu T, Tana-Aslan A. Respiratory muscle strength, exercise capacity and physical activity in patients with primary ciliary dyskinesia: A cross-sectional study. Respir Med. 2022 Jan;191:106719. doi: 10.1016/j.rmed.2021.106719. Epub 2021 Dec 17. PubMed 34952415 ↗

Individual participant data

Plan to share: No

09

Updates

1 registry update since Sep 25, 2026
Status
Not yet recruiting→Recruiting
changed Nov 4, 2026
Sites
Izmir Democracy University is now Recruiting
Nov 4, 2026
Start date
Aug 1, 2026→Jun 16, 2026 (actual)
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Not yet recruiting→Recruiting
    Izmir Democracy University is now Recruiting
    Start date Aug 1, 2026→Jun 16, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07740551
Lead sponsor
Izmir Democracy University
Responsible party
Gulsah Bargi (Principal Investigator, Izmir Democracy University) — Principal investigator
First posted
Jul 31, 2026
Start date
Jun 16, 2026
Primary completion
Aug 1, 2027 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Gülşah Barğı, Assoc Prof
Contact
gulsahbargi35@gmail.com
+90 232 299 0739
Aybüke S Demir, PT, MSc
Contact
aybukedemir1108@gmail.com
+90 543 215 0018
Gülşah Barğı, Assoc Prof
study director · Izmir Democracy University
Aybüke S Demir, PT, MSc
principal investigator · Izmir Democracy University
Kerim K Göküstün, Asst Prof
principal investigator · Izmir Democracy University
Ece Ocak, Dr
principal investigator · Izmir City Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion